Optimizing Treatment Strategies for HR+/HER2- Breast Cancer: ESR1 Mutations and Emerging Therapies - Episode 9

PostMONARCH: Dissecting Data on Sequential CDK 4/6 Inhibitors

,

The expert panel examines the subgroup data from the postMONARCH study, focusing on patients with ESR1 and PIK3CA mutations, and emphasizes the important role of CDK4/6 inhibitors in the treatment of these specific patient populations with HR+/HER2- metastatic breast cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Prevalence and Testing Strategies for ESR1
    EP. 2: Evolution of Testing Strategies for ESR1
    EP. 3: Dynamics of ESR1 Alterations and Serial Liquid Biopsies
    EP. 4: Case Presentation 1: PIK3CA Mutation With ESR1 Mutations
    EP. 5: EMERALD Study Design and Results for Elacestrant 
    EP. 6: Evolving Best Practices for ESR1 Testing
    EP. 7: Case Presentation 2: Co-mutations in ESR1 and PIK3CA
    EP. 8: PIK3CA Mutations and Delivering PI3K Inhibitors
    Now Viewing
    EP. 9: PostMONARCH: Dissecting Data on Sequential CDK 4/6 Inhibitors
    EP. 10: Combinations and Treatment Sequence Strategies in Breast Cancer
    EP. 11: Future Directions and Unmet Needs in HR+ Breast Cancer
    EP. 12: Looking Ahead: Expert Future Perspectives in HR+ Breast Cancer
    1. PostMONARCH Subgroup data in ESR1 and PIK3CA
    x